Demiurge AI进一步发现PI3K-p110α抑制剂单药和PI3K-p110δ抑制剂加PD-1抑制剂联用可作为针对2019年新型冠状病毒（COVID-19）高效安全的两项新型候选治疗方案

瑞士，星期日, 2020年2月16日 8:50AM 欧洲中部时间

Demiurge致力于利用AI为2019年新型冠状病毒（COVID-19）筛选新型候选治疗药物。基于Demiurge开发的精确广谱病毒学模型，我们对已发表的COVID-19研究数据进行了深入的分析。

在2020年2月14日所公布发现的基础上，我们今日公布磷酸肌醇3-激酶（phosphoinositide 3-kinase）抑制剂（PI3K抑制剂）关于做为COVID-19的候选治疗方案的进一步发现：

• 做为COVID-19的候选治疗方案，PI3K-p110α抑制剂比PI3K-p110δ抑制剂将具有更好的有效性和安全性。

• PI3K-p110α抑制剂与pan-class PI3K抑制剂在癌症治疗中可能出现的副作用，较少会在病毒治疗中出现，尤其是COVID-19。

• PD-1抑制剂单药，做为COVID-19的临床治疗方案，将会引发过度免疫反应。PI3K-p110δ抑制剂加PD-1抑制剂联用，是一种比PD-1抑制剂单药更加安全的临床治疗方案。

• 基于SARS冠状病毒或MERS冠状病毒测试出的候选治疗方案的有效性和安全性，仅会有限地翻译到COVID-19冠状病毒上。

在慢性病领域，药物专利的排他性和药物销售的独家性，有效激励医药企业完成漫长而昂贵的新药开发，最终普惠大众。但是在流行病领域，时间是最为稀缺的要素。公众对治疗药物需求的紧迫性和药企对治疗药物供给的独家性通常在时间上是难以兼顾的。然而我们相信，在对抗流行病对生命的威胁时，深耕于医药事业的企业和个人都会将公众福祉放在首位。争分夺秒，阻击病毒。

因此，面对COVID-19, Demiurge决定第一时间向公众公布我们上述的进一步发现，放弃平常时期申请专利保护、独家权益合作等环节。以期能尽吾之所长，协同业界上下游，尽快开展PI3K抑制剂的三期临床试验。

关于Demiurge Technologies AG

AI已成为一种新型强大的技术方法，它可以帮助人类更深入地了解疾病和更快地发现药物。但AI必须经过严格的测试，在公众的监督下证明其价值。Demiurge已经完成了90多个三期临床试验结果的预测，实现了大于80%的准确率。同时，我们在推特（Twitter）上邀请公众参与见证我们对正在进行中的全球新药三期临床试验结果的预测（@DemiurgeTech）。

因此，我们在这里基于AI提出了PI3K-p110α 抑制剂单药和PI3K-p110δ抑制剂加PD-1抑制剂联用做为COVID-19的两项新型候选治疗方案的科学假设，并公开邀请世界各地通过随机对照临床试验的方式，验证以上基于PI3K抑制剂的治疗方案是否可以安全有效地治疗COVID-19。Demiurge敦促大众在任何相关临床试验结果公布之前，不应将任何PI3K抑制剂等同于COVID-19的治疗药物擅自使用。

Disclaimers

This material is intended for information purposes only and is provided without any warranty of any kind, either expressed or implied. These statements are not guarantees of future performance, condition or results. Figures and graphs in this presentation are for illustration only and are may not match the actual scale. This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as ‘believes’, ‘expects’, ‘anticipates’, ‘projects’, ‘intends’, ‘should’,‘seeks’, ‘estimates’, ‘future’ or similar expressions or by discussion of, among other things, strategy, goals, plans or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this presentation, among others: 1 pricing and product initiatives of competitors; 2 legislative and regulatory developments and economic conditions; 3 delay or inability in obtaining regulatory approvals or bringing products to market; 4 fluctuations in currency exchange rates and general financial market conditions; 5 uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side-effects of pipeline or marketed products; 6 increased government pricing pressures; 7 interruptions in production; 8 loss of or inability to obtain adequate protection for intellectual property rights; 9 litigation; 10 loss of key executives or other employees. Demiurge Technologies AG (“Demiurge”) undertakes no duty or obligation to publicly update or revise the forward-looking statements or other information contained in this presentation. You should not view information related to the past performance of Demiurge and its affiliates or information about the market, as indicative of future results, the achievement of which cannot be assured. While some information used in this document may have been obtained from various published and unpublished sources considered to be reliable, Demiurge neither guarantees its accuracy or completeness nor accepts liability for any direct or consequential losses arising from its use. Amounts and percentages may reflect rounding adjustments and consequently totals may not appear to sum. None of the information in this presentation does, by itself, constitute an offering or an offering circular according to Article 652a of the Swiss Code of Obligations and is subject to change without notice. Any offer or solicitation with respect to any securities that may be issued by Demiurge will be made only by means of definitive offering memoranda or prospectus, which will be provided to prospective investors and will contain material information that is not set forth herein, including risk factors relating to any such investment. Before making an investment, you must obtain and carefully read all information needed to evaluate the investment, including, but not limited to the documents providing important disclosures regarding risks, fees and expenses. An investment in Demiurge may be volatile and can suffer from adverse or unexpected market moves or other adverse events. Investors may suffer the loss of their entire investment. An investment in Demiurge will be discrete from an investment in any funds or other investment programs managed by Demiurge and the results or performance of such other investment programs is not indicative of the results or performance that will be achieved by Demiurge or such investment programs.

* 中英文通告的最终解释以英文为准

媒体联系方式：
covid2019@demiurge.technology